Allarity Therapeutics Expands Stenoparib Trials, Secures Patent for Companion Diagnostic — Allarity Therapeutics, Inc.

Event summary

Stenoparib trials expanded to relapsed small cell lung cancer under VA funding, alongside ongoing ovarian cancer trials under FDA Fast Track designation.
USPTO issued Notice of Allowance for stenoparib-specific DRP® companion diagnostic patent, extending potential exclusivity by 11 years.
Q1 2026 ended with $29.8M in cash, down from $27.7M in Q1 2025, as R&D and G&A expenses remained stable.
AACR 2026 data reinforced DRP®'s ability to predict stenoparib efficacy in ovarian and colorectal cancers.
Stenoparib Phase 3-ready API manufacturing on track for Q3 2026 completion with no additional cash outlays expected.

The big picture

Allarity's expansion into small cell lung cancer trials and strengthened IP position for stenoparib come as precision oncology gains traction, with companion diagnostics becoming critical for regulatory approvals. The company's financial discipline—maintaining cash reserves while reducing share count—positions it to navigate the capital-intensive Phase 3 development phase. Success hinges on validating stenoparib's unique mechanism across multiple cancer types, particularly in platinum-resistant ovarian cancer where unmet needs remain high.

What we're watching

Clinical Validation: Whether stenoparib's dual PARP and WNT pathway inhibition will demonstrate superior efficacy in expanded cancer indications.
Regulatory Pathway: The pace at which the DRP® companion diagnostic gains regulatory acceptance for patient selection.
Financial Runway: How Allarity balances cash burn against potential funding needs for Phase 3 trials and commercialization.